All Hepatitis C articles
-
ResearchSynthetic overhaul for hepatitis C drug could ease manufacturing demands
Chemists hope their five-step synthesis will increase global accessibility of uprifosbuvir and other lifesaving antivirals
-
PodcastSofosbuvir
The hepatitis C drug that made waves when first launched – quicker to work and with fewer side effects than existing drugs, but it came with a hefty price tag
-
NewsMedicine Nobel prize goes to discoverers of hepatitis C virus
Harvey Alter, Michael Houghton and Charles Rice share prize for uncovering the disease-causing agent affecting more than 71 million people
-
ResearchHepatitis C drug lead designed to target virus RNA
Gene-to-RNA-to-medicine pipeline possible thanks to technique that reveals interactions between RNA and small molecules
-
BusinessChina approves BMS’s hepatitis C drugs
Combination is first all-oral treatment in China, where Gilead’s Sovaldi is not yet approved
-
ResearchCatalyst puts chiral twist on phosphorus drugs
Simple molecule overcomes headache of phosphorus stereochemistry in antiviral drug synthesis
-
ResearchChemoluminescent nanoparticles detect multiple deadly viruses in one go
A detection system can test for multiple viruses in one sample
-
BusinessJudge voids Merck & Co’s $200m patent claim
‘Serious misconduct’ kills case over Gilead’s hepatitis C drugs
-
BusinessGilead loses to Merck & Co in hepatitis C drug dispute
US court upholds Merck’s claim to patents related to blockbuster drugs
-
Business
Merck & Co joins hepatitis C party
New drug adds new treatment options and increases competition in premium market
-
Business
Achillion partners with Janssen to boost hepatitis C pipeline
Development deal worth up to $1.1bn includes three investigational drugs aiming to extend treatment options in fast-moving market
-
BusinessHepatitis C drug patent challenged in Europe
Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent
-
Business
J&J to buy antiviral specialist Alios
$1.75 billion deal brings Phase II compounds for hepatitis C and respiratory syncytial virus
-
Business
Gilead licenses generic hepatitis C drug in India
Company aims to head off competition and grab a slice of royalties
-
Business
Merck & Co bolsters hepatitis C pipeline with Idenix acquisition
Early-stage drugs complement Merck’s own developmental portfolio
-
BusinessNew wave of hepatitis C drugs hits US shore
J&J’s once-daily drug approved by FDA, but rivals are hot on its heels
-
Business
Vertex to cut 370 jobs
Imminent competition drives drop in its hepatitis C drug’s performance